That may include weight loss, improved insulin sensitivity, reduced visceral fat, better cardiometabolic markers, lower inflammatory burden, improved mobility, and greater capacity to exercise
Contact Biocytogen today to learn how our humanized models and disease models can support your metabolic drug discovery programs and accelerate translational success
Semaglutide has safety data extending beyond 5 years from cardiovascular outcomes trials, with an excellent profile
Premium suppliers achieve 99% or above
The combination of GLP-1, GIP and glucagon receptor activation provided superior glycemic control compared to existing GLP-1-based therapies
These symptoms usually improve as your body adjusts